According to filings with the U.S. Securities and Exchange Commission, Waltz Health is raising up to $20,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Waltz Health
Waltz is leading a new way forward for prescription care. Led by a team of industry experts, were fixing the high costs and broken experiences that define our pharmaceutical supply chain. Waltz is introducing AI-driven marketplaces that drive down costs, and new consumer tools that guide decisions on care. Our solutions are designed with payers, pharmacies, and consumers in mind. We believe that better pricing, more information and smarter tools can lower costs and empower consumers. This technology is the start of a new way of working together – making better outcomes possible for all.

To learn more about Waltz Health, visit http://www.waltzhealth.com/
Waltz Health Linkedin Page: https://www.linkedin.com/company/waltz-health/

Contact:
Lynne Okeefe, Director
847-809-6299

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.